CSPC Pharmaceutical Group Limited (CHJTF)

OTCMKTS · Delayed Price · Currency is USD
0.9800
0.00 (0.00%)
Jun 25, 2026, 9:30 AM EST
Market Cap9.75B -16.8%
Revenue (ttm)3.69B -5.9%
Net Income473.21M -22.2%
EPS0.04 -20.6%
Shares Out n/a
PE Ratio20.61
Forward PE9.50
Dividend0.04 (3.79%)
Ex-Dividend DateJun 24, 2026
Volumen/a
Open0.9800
Previous Close0.9800
Day's Range0.9800 - 0.9800
52-Week Range0.9412 - 1.3900
Beta0.73
Analystsn/a
Price Targetn/a
Earnings DateAug 21, 2026

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,... [Read more]

Sector Healthcare
Founded 1992
Employees 19,700
Stock Exchange OTCMKTS
Ticker Symbol CHJTF

Financial Performance

In 2025, CSPC Pharmaceutical Group's revenue was 26.01 billion, a decrease of -10.35% compared to the previous year's 29.01 billion. Earnings were 3.88 billion, a decrease of -10.30%.

Financial numbers in CNY Financial Statements

News

CSPC Pharmaceutical Group Earnings release: Q1 2026

CSPC Pharmaceutical Group released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.

4 weeks ago - Filings

CSPC Pharmaceutical Group Slides: Q1 2026

CSPC Pharmaceutical Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 27, 2026.

4 weeks ago - Filings

CSPC Pharmaceutical Group Earnings release: Q4 2025

CSPC Pharmaceutical Group released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.

3 months ago - Filings

CSPC Pharmaceutical Group Slides: Q4 2025

CSPC Pharmaceutical Group has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 25, 2026.

3 months ago - Filings

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.

5 months ago - WSJ

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related condit...

5 months ago - Reuters

CSPC Pharmaceutical Group Earnings release: Q3 2025

CSPC Pharmaceutical Group released its Q3 2025 earnings on November 19, 2025, summarizing the period's financial results.

7 months ago - Filings

CSPC Pharmaceutical Group Slides: Q3 2025

CSPC Pharmaceutical Group has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 19, 2025.

7 months ago - Filings

CSPC Pharmaceutical Group Quarterly report: H1 2025

CSPC Pharmaceutical Group has published its H1 2025 quarterly earnings report on August 22, 2025.

11 months ago - Filings

CSPC Pharmaceutical Group Earnings release: H1 2025

CSPC Pharmaceutical Group released its H1 2025 earnings on August 22, 2025, summarizing the period's financial results.

11 months ago - Filings

CSPC Pharmaceutical Group Slides: H1 2025

CSPC Pharmaceutical Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 22, 2025.

11 months ago - Filings